TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36168693

Group type: EXPERIMENTAL
Intervention: Picamilon Ginkgo
Number of subjects: 278

Group type: COMPARATOR
Intervention: Ginkgo biloba extract
Number of subjects: 278
Study: 35449015

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg daily
Number of subjects: 25210

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 25210
Study: 34236915

Group type: COMPARATOR
Intervention: Triple antithrombotic therapy with clopidogrel
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy with potent P2Y12 inhibitors (ticagrelor or prasugrel)
Number of subjects: 65
Study: 32114213

Group type: EXPERIMENTAL
Intervention: Robotized needle holder (JAIMY; Endocontrol, Grenoble, France)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional needle holders
Number of subjects: 20
Study: 35353300

Group type: EXPERIMENTAL
Intervention: Vaginal Cuff Closure Model (VC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: dV-Trainer® (VR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-completion survey
Number of subjects: 30
Study: 32948369

Group type: COMPARATOR
Intervention: HLA-DRB1*01:02 allele frequency in COPD patients (6.54%)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*01:02
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*15:01
Number of subjects: 214
Study: 32762229

Group type: EXPERIMENTAL
Intervention: Fractional ultrapulsed CO2 laser (group L, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High‐intensity focused ultrasound (group U, n=30)
Number of subjects: 60
Study: 34971723

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Midazolam (30 μg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 24
Study: 33068444

Group type: EXPERIMENTAL
Intervention: Secukinumab low dose (LD: 75/75/150 mg)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Secukinumab high dose (HD: 75/150/300 mg)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Secukinumab low dose (LD)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Secukinumab high dose (HD)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Etanercept (0.8 mg/kg up to a max of 50 mg)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 32243575

Group type: EXPERIMENTAL
Intervention: Oral-B iO electric toothbrush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sonic toothbrush
Number of subjects: 0
Study: 32995960

Group type: COMPARATOR
Intervention: Normoxia (SL; simulated altitude/end-exercise arterial oxygen saturation=0 m/96%)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (MH; 2200 m/90%)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Severe hypoxia (SH; 4200 m/79%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Muscle oxygenation in MH compared to SL
Number of subjects: 11

Group type: COMPARATOR
Intervention: Muscle oxygenation in SH compared to SL
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Peak twitch amplitude with single and paired electrical stimuli
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Maximal torque during brief and sustained MVCs
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Voluntary activation measured using transcranial magnetic stimulation
Number of subjects: 11
Study: 35926824

Group type: EXPERIMENTAL
Intervention: GSP301 nasal spray (olopatadine hydrochloride 665 μg and mometasone furoate 25 μg), 1 spray/each nostril twice daily for 14 days
Number of subjects: 446

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: GSP301 nasal spray
Number of subjects: 446
Study: 33372745

Group type: EXPERIMENTAL
Intervention: Enoxaparin adjusted to anti‐Xa level of 0.2‐0.5 international units/mL started at less than 24 hours after insertion of central venous catheter
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care without placebo
Number of subjects: 47
Study: 36268462

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs) - apixaban, edoxaban, rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apixaban and rivaroxaban
Number of subjects: 0
Study: 32692240

Group type: EXPERIMENTAL
Intervention: Improved Hospital Elderly Life Program (HELP) combined with conventional nursing for 2 weeks
Number of subjects: 106
Study: 35920133

Group type: EXPERIMENTAL
Intervention: dilpacimab + FOLFIRI
Number of subjects: 66

Group type: COMPARATOR
Intervention: bevacizumab + FOLFIRI
Number of subjects: 66
Study: 33177129

Group type: EXPERIMENTAL
Intervention: Visualisation and pictorial representation of abdominal aortic calcification (AAC) results at baseline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control group receiving AAC results at 12 weeks
Number of subjects: 0
Study: 32720783

Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention (DEI, N=27)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diet only intervention (DI, N=27)
Number of subjects: 60
Study: 32456646

Group type: EXPERIMENTAL
Intervention: Hearing impairment (measured by asking participants if they had hearing problems)
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Severity of hearing impairment (identified by pure tone average of hearing thresholds at 0.5, 1, 2, and 4 kHz)
Number of subjects: 1248
Study: 36453014

Group type: EXPERIMENTAL
Intervention: G-Rup® syrup (30 ml twice daily for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34842573

Group type: EXPERIMENTAL
Intervention: Selenase (intravenous selenium) for 5 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (saline) for 5 days
Number of subjects: 50
Study: 34566855

Group type: EXPERIMENTAL
Intervention: Active rESWT
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham-placebo rESWT
Number of subjects: 100
Study: 35197060

Group type: EXPERIMENTAL
Intervention: Permethrin-treated baby wraps
Number of subjects: 50

Group type: COMPARATOR
Intervention: Untreated baby wraps (control)
Number of subjects: 50
Study: 33609741

Group type: EXPERIMENTAL
Intervention: Rapid Eye Movement (REM) sleep
Number of subjects: 0
Study: 32063531

Group type: EXPERIMENTAL
Intervention: Partial removable dental prosthesis (PRDP) group (n=79)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Shortened dental arch (SDA) group (n=71)
Number of subjects: 150
Study: 33891831

Group type: COMPARATOR
Intervention: Placebo treatment, n = 713
Number of subjects: 2612

Group type: COMPARATOR
Intervention: Placebo treatment, n = 751
Number of subjects: 2612

Group type: EXPERIMENTAL
Intervention: Nasal polyps presence
Number of subjects: 2612

Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 2612

Group type: EXPERIMENTAL
Intervention: Technical factors (laboratory differences, time from collection to analysis)
Number of subjects: 2612
Study: 32894044

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 33009352

Group type: EXPERIMENTAL
Intervention: Moderate intensity resistance exercise (3 sets of 10 repetitions at 68% 1RM)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (4 sets of 6 repetitions at 85% 1RM)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Rest (no exercise)
Number of subjects: 9
Study: 33592868

Group type: EXPERIMENTAL
Intervention: A+HA (20 mL daily for 8 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (20 mL daily for 8 weeks)
Number of subjects: 47
Study: 32769414

Group type: EXPERIMENTAL
Intervention: 10 kHz spinal cord stimulation (10 kHz-SCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-frequency spinal cord stimulation (LF-SCS)
Number of subjects: 0
Study: 36306168

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (2 U/kg for cycle 1 only, 8 U/kg and 16 U/kg) followed by a tailored home exercises therapy programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA treatment cycles
Number of subjects: 0
Study: 34955131

Group type: EXPERIMENTAL
Intervention: HFNC
Number of subjects: 44

Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 44
Study: 36907876

Group type: EXPERIMENTAL
Intervention: Little ACF (intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four digital lectures about child development and parenting (active control)
Number of subjects: 0
Study: 33680312

Group type: EXPERIMENTAL
Intervention: Blindfolded training (BT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard training (ST)
Number of subjects: 85
Study: 34285430

Group type: EXPERIMENTAL
Intervention: Preoperative respiratory rehabilitation (group A)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Postoperative rehabilitation only (group B)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study: 35007482

Group type: EXPERIMENTAL
Intervention: Therapist-administered hypnosis (Group A) for 8 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Self-hypnosis (Group B) for 8 weeks
Number of subjects: 70
Study: 34840503

Group type: EXPERIMENTAL
Intervention: Community Pharmacy-Based Intervention (CPBI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 100
Study: 32312261

Group type: EXPERIMENTAL
Intervention: Ginger extract 500 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 80
Study: 35481442

Group type: EXPERIMENTAL
Intervention: Gabapentin 20 mg/kg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 32581409

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-invasive positive pressure ventilation (NPPV)
Number of subjects: 32
Study: 36181471

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg (or maximum-tolerated dose)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 55
Study: 34467796

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS); applied over the left dorsolateral prefrontal cortex for 10 consecutive weekdays.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham stimulation; applied over the left dorsolateral prefrontal cortex for 10 consecutive weekdays.
Number of subjects: 35
Study: 33346522

Group type: EXPERIMENTAL
Intervention: LVS (daytime serum and nighttime serum) with basic skin care regimen (moisturizer and SPF 35 sunscreen)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Basic skin care regimen only (control)
Number of subjects: 61
Study: 35040798

Group type: EXPERIMENTAL
Intervention: Wearable technology-assisted combined home-based exercise program
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55
Study: 35113899

Group type: EXPERIMENTAL
Intervention: Active patient participation during rehabilitation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Mobilisation session type
Number of subjects: 108

Group type: COMPARATOR
Intervention: Physiotherapy-led rehabilitation sessions
Number of subjects: 108
Study: 33531563

Group type: EXPERIMENTAL
Intervention: Spaced-learning (2-h weekly sessions over 4 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mass-learning (single 8-h session)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 35790787

Group type: EXPERIMENTAL
Intervention: ADT plus abiraterone
Number of subjects: 1058

Group type: COMPARATOR
Intervention: ADT with placebo
Number of subjects: 1058
Study: 34425666

Group type: EXPERIMENTAL
Intervention: CHX 0.12% SPDD alcohol free
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CHX 0.20% SPDD alcohol free
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CHX 0.12% alcohol free with ADS
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CHX 0.20% alcohol free with ADS
Number of subjects: 84
Study: 33895559

Group type: EXPERIMENTAL
Intervention: Eucaloric ketogenic diet (EKD)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Eucaloric standard diet
Number of subjects: 102
Study: 35917059

Group type: EXPERIMENTAL
Intervention: macitentan 10 mg
Number of subjects: 492

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 492
Study: 33843297

Group type: EXPERIMENTAL
Intervention: Physical activity on prescription (n=72)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Advice session (n=69)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study: 34386824

Group type: EXPERIMENTAL
Intervention: Open surgical exposure with orthodontic treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Closed surgical exposure with orthodontic treatment
Number of subjects: 120
Study: 33348644

Group type: EXPERIMENTAL
Intervention: Definitive abutment (DEF)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Healing abutment (HEA)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 1 mm high abutment (Subgroup A)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 2 mm high abutment (Subgroup B)
Number of subjects: 147
Study: 35364630

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 50
Study: 33632347

Group type: EXPERIMENTAL
Intervention: Tobacco Intensive Motivational Estimated Risk tool (TIMER)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 5 A's intervention
Number of subjects: 160
Study: 33147593

Group type: EXPERIMENTAL
Intervention: Sealed test surfaces
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not sealed)
Number of subjects: 48
Study: 616788562

Group type: EXPERIMENTAL
Intervention: Strength training (8 weeks, 3 sessions per week, each session 65 minutes)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 16
Study: 33519166

Group type: EXPERIMENTAL
Intervention: Food insecure group
Number of subjects: 102
Study: 35817131

Group type: EXPERIMENTAL
Intervention: Palm Nut (hazelnut cocoa palm oil-rich spread)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Butter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 30
Study: 32889876

Group type: EXPERIMENTAL
Intervention: Robotic Distal Gastrectomy (RDG)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Laparoscopic Distal Gastrectomy (LDG)
Number of subjects: 300
Study: 33278521

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 3004

Group type: EXPERIMENTAL
Intervention: Endotracheal Intubation (ETI)
Number of subjects: 3004

Group type: COMPARATOR
Intervention: Control (Bag-valve-mask ventilation only)
Number of subjects: 3004

Group type: EXPERIMENTAL
Intervention: All interventions (LT and ETI)
Number of subjects: 3004
Study: 32908914

Group type: EXPERIMENTAL
Intervention: Wooden skull models
Number of subjects: 120

Group type: COMPARATOR
Intervention: Natural skull models (Control)
Number of subjects: 120
Study: 36451109

Group type: EXPERIMENTAL
Intervention: Radiomics signature (radscore)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Radiomics models (both signature and nomogram)
Number of subjects: 152
Study: 34916636

Group type: EXPERIMENTAL
Intervention: Saltwater mouth rinse
Number of subjects: 37

Group type: COMPARATOR
Intervention: Chlorhexidine mouth rinse
Number of subjects: 37
Study: 34293018

Group type: EXPERIMENTAL
Intervention: High-compliance matting
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low-compliance matting
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low-compliance matting with a backboard
Number of subjects: 27
Study: 32507132

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) treatment, 12 min/session, three sessions/week for four weeks.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment (control group), blinded to participants, for two weeks.
Number of subjects: 20
Study: 35484279

Group type: EXPERIMENTAL
Intervention: Music intervention group (MIG)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 72
Study: 34444974

Group type: EXPERIMENTAL
Intervention: BB-12 yogurt
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control yogurt
Number of subjects: 62
Study: 32331031

Group type: EXPERIMENTAL
Intervention: Biofeedback and analgesics
Number of subjects: 50

Group type: COMPARATOR
Intervention: Analgesics alone
Number of subjects: 50
Study: 35136116

Group type: EXPERIMENTAL
Intervention: Wet perlite
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dry perlite
Number of subjects: 13

Group type: COMPARATOR
Intervention: High density snow
Number of subjects: 13
Study: 33864139

Group type: EXPERIMENTAL
Intervention: MF-based radiomic signature
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Radiomic-clinical nomogram
Number of subjects: 217

Group type: COMPARATOR
Intervention: MV-based radiomic signature
Number of subjects: 217

Group type: COMPARATOR
Intervention: Clinico-radiological signature
Number of subjects: 217
Study: 32355569

Group type: COMPARATOR
Intervention: ES+HIV
Number of subjects: 1773

Group type: COMPARATOR
Intervention: ES-only
Number of subjects: 1773

Group type: COMPARATOR
Intervention: HIV-only
Number of subjects: 1773

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1773
Study: 35260450

Group type: EXPERIMENTAL
Intervention: ACE inhibitors and angiotensin receptor blockers
Number of subjects: 0
Study: 36435541

Group type: EXPERIMENTAL
Intervention: Building Closer Friendships (BCF)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 55
Study: 32556113

Group type: EXPERIMENTAL
Intervention: TwinrabTM (docaravimab and miromavimab)
Number of subjects: 308

Group type: COMPARATOR
Intervention: HRIG (Imogam® Rabies‐HT)
Number of subjects: 308
Study: 32130125

Group type: EXPERIMENTAL
Intervention: Community antistigma campaign with training of lay village health workers and primary care doctors; use of electronic clinical decision support system.
Number of subjects: 900
Study: 35993376

Group type: EXPERIMENTAL
Intervention: Engagement with IT posts
Number of subjects: 869

Group type: COMPARATOR
Intervention: Control (prescription drug misuse posts)
Number of subjects: 869
Study: 34735908

Group type: EXPERIMENTAL
Intervention: RPGE (375 mg, 2 tablets, 2 times/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32847622

Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) training package (2-day standard course)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) training package (1-day course)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mental health awareness-raising session
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Peer support service
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Peer support service re-advertisement
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fidelity of MHFA training delivery
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Adherence to operational guidelines for peer support service
Number of subjects: 25
Study: 35149326

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 34503629

Group type: EXPERIMENTAL
Intervention: Ketone ester (KE) drink
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo control drink
Number of subjects: 11
Study: 32371670

Group type: EXPERIMENTAL
Intervention: Lu-DOTATATE + capecitabine
Number of subjects: 8
Study: 34396784

Group type: EXPERIMENTAL
Intervention: Fasted state (high NEFA levels)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Glucose-fed state (low NEFA levels)
Number of subjects: 9
Study: 36168956

Group type: EXPERIMENTAL
Intervention: Hypothermic temperature control (32-34°C for 24 hours)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Normothermia (controlled at 37.0°±0.9°C for 48 hours)
Number of subjects: 249
Study: 33908297

Group type: EXPERIMENTAL
Intervention: Distal superficial femoral vein (DSFV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Axillary vein (AV)
Number of subjects: 60
Study: 32682074

Group type: EXPERIMENTAL
Intervention: BGF MDI (160/7.2/4.8 μg per actuation) with a 10-second breath-hold
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BGF MDI (160/7.2/4.8 μg per actuation) with a 3-second breath-hold
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BGF MDI (160/7.2/4.8 μg per actuation)
Number of subjects: 10
Study: 35689881

Group type: EXPERIMENTAL
Intervention: uPA positive tumors
Number of subjects: 303

Group type: COMPARATOR
Intervention: PAI-1 expression
Number of subjects: 303

Group type: COMPARATOR
Intervention: uPA/PAI-1 ratio
Number of subjects: 303
Study: 34497027

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (stimulated on bilateral Zusanli, Shangjuxu, and Sanyinjiao acupoints in lower limbs for 30 minutes each time, total 4 times)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Sham treatment (without currents delivered)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Number of subjects: 610
Study: 34312156

Group type: EXPERIMENTAL
Intervention: Kilkari mobile health messaging program
Number of subjects: 54
Study: 34999268

Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise (EX)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Health education control (HE)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Craving during treatment
Number of subjects: 135
Study: 33947608

Group type: EXPERIMENTAL
Intervention: Axitinib monotherapy
Number of subjects: 1955

Group type: COMPARATOR
Intervention: Axitinib + IO
Number of subjects: 1955

Group type: COMPARATOR
Intervention: Other TKI
Number of subjects: 1955
Study: 32109422

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 34610482

Group type: EXPERIMENTAL
Intervention: solriamfetol
Number of subjects: 64

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study: 35473742

Group type: EXPERIMENTAL
Intervention: Mobile health intervention (informational and testimonial video about opioid tapering + two text messages per day for 28 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (multidisciplinary pain management)
Number of subjects: 40